EANS-Stimmrechte: Epigenomics AG / Korrektur der Veröffentlichung gemäß § 26
Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung vom 10. Aug. 2012, 14:13
Uhr

(ots) - --------------------------------------------------------------------------------
Stimmrechtsmitteilung übermittelt durch euro adhoc mit dem Ziel einer
europaweiten Verbreitung. Für den Inhalt ist der Emittent verantwortlich.
--------------------------------------------------------------------------------

Mitteilung nach § 21 Abs. 1 WpHG (Aktie)

Correction of Voting Rights Notification dated 10 August 2012: Release of a
Voting Rights Notification Pursuant to Sec. 26 para. 1 WpHG (German Securities
Trading Act) with the Aim of a Europe-wide Distribution

Issuer:

Epigenomics AG
Kleine Präsidentenstr. 1
10178 Berlin
Germany

Corrected Voting Rights Notification:

On 6 August 2012, Baker Bros. Advisors, LLC, New York, NY, USA notified
Epigenomics AG of voting rights in Epigenomics AG pursuant to sec. 21 para. 1
WpHG in connection with sec. 22 para. 1 sent. 1 no. 6 WpHG as follows:

On 12 April 2012, the share of Baker Bros. Advisors, LLC in the voting rights
of Epigenomics AG exceeded the 3 per cent threshold as well as the 5 per cent
threshold of sec. 21 para. 1 WpHG and amounted, as at this date, to 6.33 per
cent of the voting rights (557,956 voting rights) in Epigenomics AG.

6,33 per cent of the voting rights (557,956 voting rights) are attributed to
Baker Bros. Advisors, LLC, pursuant to sec. 22 para. 1 sent. 1 no. 6 WpHG inter
alia through Baker Brothers Life Sciences, L.P.

Furthermore, on 6 August 2012, Baker Bros. Advisors, LLC, New York, NY, USA
notified Epigenomics AG of voting rights in Epigenomics AG pursuant to sec. 21
para. 1 WpHG in connection with sec. 22 para. 1 sent. 1 no. 6 WpHG as follows:

On 31 July 2012, the share of Baker Bros. Advisors, LLC in the voting rights of
Epigenomics AG fell below the 5 per cent threshold of sec. 21 para. 1 WpHG and
amounted, as at this date, to 4.61 per cent of the voting rights (406,186

voting rights) in Epigenomics AG.

4.61 per cent of the voting rights (406,186 voting rights) are attributed to
Baker Bros. Advisors, LLC, pursuant to sec. 22 para. 1 no. 6 WpHG inter alia
through Baker Brothers Life Sciences, L.P.

Furthermore, on 6 August 2012 and 8 August 2012, Julian Baker, USA, notified
Epigenomics AG of voting rights in Epigenomics AG pursuant to sec. 21 para. 1
WpHG in connection with sec. 22 para. 1 sent. 1 no. 1 and no. 6, sent. 2 WpHG
and sec. 22 para. 2 WpHG as follows:

On 31 July 2012, the share of Julian Baker in the voting rights of Epigenomics
AG fell below the 5 per cent threshold of sec. 21 para. 1 WpHG and amounted, as
at this date, to 4.61 per cent of the voting rights (406,186 voting rights) in
Epigenomics AG.

All 4.61 per cent of the voting rights (406,186 voting rights) are attributed
to Julian Baker pursuant to sec. 22 para. 1 sent. 1 no. 1 WpHG of which 4.49
per cent of the voting rights (396,198 voting rights) are attributed through
the following entities controlled by Julian Baker the voting rights of which
exceed 3 per cent:

- Baker Brothers Life Sciences Capital (GP), LLC
- Baker Brothers Life Sciences Capital, L.P.
- Baker Brothers Life Sciences, L.P.

The 4.61 per cent of the voting rights (406,186 voting rights) are also
attributed to Julian Baker pursuant to sec. 22 para. 1 sent. 1 no. 6, sent. 2

WpHG. In addition, all 4.61 per cent of the voting rights are attributed to
Julian Baker pursuant to sec. 22 para. 2 WpHG. 4.49 per cent of the voting
rights (396,198 voting rights) are attributed from Baker Brothers Life
Sciences, L.P.

Furthermore, on 6 August 2012 and 8 August 2012, Felix J. Baker, USA, notified
Epigenomics AG of voting rights in Epigenomics AG pursuant to sec. 21 para. 1
WpHG in connection with sec. 22 para. 1 sent. 1 no.1 and no. 6, sent. 2 WpHG
and sec. 22 para. 2 WpHG as follows:

On 31 July 2012, the share of Felix J. Baker in the voting rights of
Epigenomics AG fell below the 5 per cent threshold of sec. 21 para. 1 WpHG and
amounted, as at this date, to 4.61 per cent of the voting rights (406,186
voting rights) in Epigenomics AG.

All 4.61 per cent of the voting rights (406,186 voting rights) are attributed
to Felix J. Baker pursuant to sec. 22 para. 1 sent. 1 no.1 WpHG of which 4.49
per cent of the voting rights (396,198 voting rights) are attributed through
the following entities controlled by Felix Baker the voting rights of which
exceed 3 per cent:

- Baker Brothers Life Sciences Capital (GP), LLC
- Baker Brothers Life Sciences Capital, L.P.
- Baker Brothers Life Sciences, L.P.

The 4.61 per cent of the voting rights (406,186 voting rights) are also

attributed to Felix J. Baker pursuant to sec. 22 para. 1 sent. 1 no. 6, sent. 2
WpHG. In addition, all 4.61 per cent of the voting rights are attributed to
Felix J. Baker pursuant to sec. 22 para. 2 WpHG. 4.49 per cent of the voting
rights (396,198 voting rights) are attributed from Baker Brothers Life
Sciences, L.P.

Furthermore, on 6 August 2012, Baker Brothers Life Sciences Capital (GP), LLC,
New York, NY, USA notified Epigenomics AG of voting rights in Epigenomics AG
pursuant to sec. 21 para. 1 WpHG in connection with sec. 22 para. 1 sent. 1 no.
1 WpHG and sec. 22 para. 2 WpHG as follows:

On 31 July 2012, the share of Baker Brothers Life Sciences Capital (GP), LLC in
the voting rights of Epigenomics AG fell below the 5 per cent threshold of sec.
21 para. 1 WpHG and amounted, as at this date, to 4.61 per cent of the voting
rights (406,186) in Epigenomics AG.

4.49 per cent of the voting rights (396,198 voting rights) are attributed to
Baker Brothers Life Sciences Capital (GP), LLC pursuant to sec. 22 para. 1
sent. 1 no. 1 WpHG through the following entities controlled by Baker Brothers
Life Sciences Capital (GP), LLC the voting rights of which exceed 3 per cent:

- Baker Brothers Life Sciences Capital, L.P.
- Baker Brothers Life Sciences, L.P.

0.11 per cent of the voting rights (9,988 voting rights) are attributed to

Baker Brothers Life Sciences Capital (GP), LLC pursuant to sec. 22 para. 2
WpHG.

Furthermore, on 6 August 2012, Baker Brothers Life Sciences Capital, L.P., New
York, NY, USA notified Epigenomics AG of voting rights in Epigenomics AG
pursuant to sec. 21 para. 1 WpHG in connection with sec. 22 para. 1 sent. 1 no.
1 WpHG and sec. 22 para. 2 WpHG as follows:

On 31 July 2012, the share of Baker Brothers Life Sciences Capital, L.P. in the
voting rights of Epigenomics AG fell below the 5 per cent threshold of sec. 21
para. 1 WpHG and amounted, as at this date, to 4.61 per cent of the voting
rights (406,186) in Epigenomics AG.

4.49 per cent of the voting rights (396,198 voting rights) are attributed to
Baker Brothers Life Sciences Capital, L.P. pursuant to sec. 22 para. 1 sent. 1
no. 1 WpHG through the following entity controlled by Baker Brothers Life
Sciences Capital, L.P. the voting rights of which exceed 3 per cent:

- Baker Brothers Life Sciences, L.P.

0.11 per cent of the voting rights (9,988 voting rights) are attributed to
Baker Brothers Life Sciences Capital, L.P. pursuant to sec. 22 para. 2 WpHG.

Furthermore, on 6 August 2011, Baker Brothers Life Sciences, L.P., New York,
NY, USA notified Epigenomics AG of voting rights in Epigenomics AG pursuant to
sec. 21 para. 1 WpHG in connection with sec. 22 para. 2 WpHG as follows:

On 31 July 2012, the share of Baker Brothers Life Sciences, L.P. in the voting
rights of Epigenomics AG fell below the 5 per cent threshold of sec. 21 para. 1
WpHG and amounted, as at this date, to 4.61 per cent of the voting rights
(406,186 voting rights) in Epigenomics AG.

0.11 per cent of the voting rights (9,988 voting rights) are attributed to
Baker Brothers Life Sciences, L.P. pursuant to sec. 22 para. 2 WpHG.

Furthermore, on 6 August 2012, 14159 Capital (GP), LLC, New York, NY, USA
notified Epigenomics AG of voting rights in Epigenomics AG pursuant to sec. 21
para. 1 WpHG in connection with sec. 22 para. 1 sent. 1 no. 1 WpHG and sec. 22
para. 2 WpHG as follows:

On 31 July 2012, the share of 14159 Capital (GP), LLC in the voting rights of
Epigenomics AG fell below the 5 per cent threshold of sec. 21 para. 1 WpHG and
amounted, as at this date, to 4.61 per cent of the voting rights (406,186
voting rights) in Epigenomics AG.

0.11 per cent of the voting rights (9,988 voting rights) are attributed to
14159 Capital (GP), LLC pursuant to sec. 22 para. 1 sent. 1 no. 1 WpHG.

4.49 per cent of the voting rights (396,198 voting rights) are attributed to
14159 Capital (GP), LLC pursuant to sec. 22 para. 2 WpHG through Baker Brothers
Life Sciences, L.P.

Furthermore, on 6 August 2012, 14159 Capital, L.P., New York, NY, USA notified
Epigenomics AG of voting rights held in Epigenomics AG pursuant to sec. 21
para. 1 WpHG in connection with sec. 22 para. 1 sent. 1 no. 1 WpHG and sec. 22
para.2 WpHG as follows:

On 31 July 2012, the share of 14159 Capital, L.P. in the voting rights of
Epigenomics AG fell below the 5 per cent threshold of sec. 21 para. 1 WpHG and
amounted, as at this date, to 4.61 per cent of the voting rights (406,186
voting rights) in Epigenomics AG.

0.11 per cent of the voting rights (9,988 voting rights) are attributed to
14159 Capital, L.P. pursuant to sec. 22 para. 1 sent. 1 no. 1 WpHG.

4.49 per cent of the voting rights (369,198 voting rights) are attributed to
14159 Capital, L.P. pursuant to sec. 22 para. 2 WpHG through Baker Brothers
Life Sciences, L.P.

Furthermore, on 6 August 2012 and 8 August 2012, 14159, L.P., New York, NY,
USA, notified Epigenomics AG of voting rights in Epigenomics AG pursuant to
sec. 21 para. 1 WpHG in connection with sec. 22 para.2 WpHG as follows:

On 31 July 2012, the share of 14159, L.P. in the voting rights of Epigenomics
AG fell below the 5 per cent threshold of sec. 21 para. 1 WpHG and amounted, as
at this date, to 4.61 per cent of the voting rights (406,186 voting rights) in
Epigenomics AG.

4.49 per cent of the voting rights (369,198 voting rights) are attributed to
14159, L.P. pursuant to sec. 22 para. 2 WpHG through Baker Brothers Life
Sciences, L.P.

Date of release: 17 August 2012

Epigenomics AG
The Executive Board

Rückfragehinweis:
Antje Zeise | CIRO
Manager IR/PR
Epigenomics AG
Tel: +49 30 24345 386
antje.zeise(at)epigenomics.com

Ende der Mitteilung euro adhoc
--------------------------------------------------------------------------------

Emittent: Epigenomics AG
Kleine Präsidentenstraße 1
D-10178 Berlin
Telefon: +49 30 24345-0
FAX: +49 30 24345-555
Email: ir(at)epigenomics.com
WWW: http://www.epigenomics.com
Branche: Biotechnologie
ISIN: DE000A1K0516
Indizes: Prime All Share, Technology All Share
Börsen: Freiverkehr: Berlin, München, Hamburg, Düsseldorf, Stuttgart,
Regulierter Markt/Prime Standard: Frankfurt
Sprache: Deutsch

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: ots
Datum: 17.08.2012 - 13:46 Uhr
Sprache: Deutsch
News-ID 702109
Anzahl Zeichen: 12318

Kontakt-Informationen:

Kategorie:

Biotechnologie

Diese Pressemitteilung wurde bisher 0 mal aufgerufen.

DGAP-News: Epigenomics AG: Epigenomics AG begrüßt Kostenerstattung des Septin ...

DGAP-News: Epigenomics AG / Schlagwort(e): Sonstiges Epigenomics AG: Epigenomics AG begrüßt Kostenerstattung des Septin9-Bluttests durch französische Krankenversicherung 12.12.2013 / 08:45 -------------------------------------------------------- ...

DGAP-News: Epigenomics AG: Epigenomics AG gibt Einberufung des Expertengremiums ...

DGAP-News: Epigenomics AG / Schlagwort(e): Sonstiges Epigenomics AG: Epigenomics AG gibt Einberufung des Expertengremiums der FDA zu Epi proColon(R) bekannt 27.11.2013 / 16:30 --------------------------------------------------------------------- B ...

www.GewinnerAktien.com ? Epigenomics bald bei 10 Euro? GewinnerAktie in dieser A ...

n.com - Epigenomics bald bei 10 Euro? GewinnerAktie in dieser Ausgabe Sehr geehrte Damen und Herren, die Epigenomics AG mit Hauptsitz in Berlin ist ein deutsch-amerikanisches Krebsdiagnostik-Unternehmen welches 1998 gegründet wurde. Um die Ent ...

Alle Meldungen von Epigenomics AG